Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers

NCT02152995 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02152995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02152995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 14, 2014
Completion date
February 5, 2027
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic thyroid gland carcinoma, poorly differentiated thyroid gland carcinoma, recurrent thyroid gland carcinoma, refractory thyroid gland carcinoma, stage iv thyroid gland follicular carcinoma ajcc v7, stage iv thyroid gland papillary carcinoma ajcc v7, stage iva thyroid gland follicular carcinoma ajcc v7, stage iva thyroid gland papillary carcinoma ajcc v7, stage ivb thyroid gland follicular carcinoma ajcc v7, stage ivb thyroid gland papillary carcinoma ajcc v7, stage ivc thyroid gland follicular carcinoma ajcc v7, stage ivc thyroid gland papillary carcinoma ajcc v7